The ravulizumab will be administered via IV infusion as below dosage regimen

3 trials

Sponsors

Yokosawa Jun, Sugita Yuko

Conditions

COVID 19 severe pneumonia, acute lung injury, or ARDS COVID-19Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplantation (HSCT) Thrombotic Microangiopathy TMA

Phase 3

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab in Patients With COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome

Active, not recruitingJPRN-jRCT2031200126

Yokosawa JunCOVID 19 severe pneumonia, acute lung injury, or ARDS COVID-19

Start: 2020-09-10Target: 270Updated: 2026-06-29

Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant

Active, not recruitingJPRN-jRCT2071200071

Sugita YukoThrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplantation (HSCT) Thrombotic Microangiopathy TMA

Start: 2020-12-17Target: 184Updated: 2026-05-25

Study of Ravulizumab in Pediatric Participants With HSCT-TMA

Active, not recruitingJPRN-jRCT2071200070

Sugita YukoThrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplantation (HSCT) Thrombotic Microangiopathy TMA

Start: 2020-12-11Target: 40Updated: 2026-06-29